Google Ventures, the investment arm tasked with spending the search giant’s billions on exciting new companies, released its annual report last night. Interestingly, the majority of its money did not go into the areas of consumer internet services, mobile apps, and enterprise software that Google is best known for. Instead, of the $1.6 billion it has under management, it put a whopping 35 percent of its new bets in 2014 into the category of life sciences and health, way up from less than 10 percent in the two years prior.
Conducted by Brian Duggan via email in August 2011
Brian Duggan: Can you please share with our readers a little of your background, and how you personally got interested in Telomere Science and its relationship with healthy aging?
Maria Blasco: After I did my PhD in Madrid, I was working at one of the leading Molecular Biology Institutes in Madrid, founded by Nobel Prize Lauretate Severo Ochoa. My supervisor, Dr. Margarita Salas, had the highest opinion of research performed at the Cold Spring Harbor Laboratory (CSHL) in New York where she knew its Director, Bruce Stillman. Therefore, in the early nineties, when I saw that there was a new Junior Group, headed by Carol W. Greider, working with the enzyme telomerase, it was clear to me that I had to work in that Group.
Conducted by Brian Duggan June 6, 2011 in New York City
Brian Duggan: Can you tell me about your original interest in healthy aging and Telomere Science?
Noel Patton: I started to notice the inflictions of old age setting in, such as a stiff knee and whatever, so I got interested in anti-aging medicine at that time, that’s 15 years ago, for myself. At that time, anti-aging medicine was pretty primitive and had very few legitimate people in it.